ArticleBMC medicine2021

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.

Yongchang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.